Biggest Insulin Maker May Build Diabetes Drug Plant in U.S.
An operator inspects production at the Kalundborg Novo Nordisk A/S insulin production facility in Denmark. Source: Novo Nordisk A/S via Bloomberg
This article is for subscribers only.
About 90 minutes from Copenhagen, at a site the size of 140 soccer fields, the world’s largest maker of insulin runs its only factory making active ingredients for diabetes therapies. Novo Nordisk A/S may soon change that with a new U.S. facility.
The Danish drugmaker is considering building a factory overseas to make an oral version of a medicine for type 2 diabetes called semaglutide, Chief Executive Officer Lars Rebien Soerensen said in an interview at Novo’s headquarters in Bagsvaerd. It’s one of several experimental pills that he says could “revolutionize the company.”